ArticleFrontiers in endocrinology2025
The predictive value of anti-Müllerian hormone on embryo quality in PGT-A cycles analysis.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Although anti-Müllerian hormone (AMH) is a well-established predictor of oocyte number in assisted reproduction (ART) applications, its potential to reflect embryo quality in ART cycles remains uncertain. This study explored the association between AMH levels and embryo quality, using aneuploidy rates from preimplantation genetic testing for aneuploidy (PGT-A) as an objective indicator of embryo quality. Methods: A retrospective analysis was performed on patients (excluding those with male factor infertility) who underwent PGT-A at the Reproduction and Genetics Center of Suzhou Municipal Hospital (2018-2022). Patients were stratified by age (<35, 35-37, ≥38 years), body mass index (BMI) (<18.5, 18.5-25, ≥25 kg/m²), number of viable embryos (1-2, 3-4, ≥5), and AMH levels. Group comparisons used independent samples t-test, and correlations with embryo quality were analyzed via logistic regression. Results: In 542 PGT-A cycles, AMH levels, euploidy and mosaicism rates negatively correlated with age, while, aneuploidy rates were positively correlated with age. BMI group showed AMH levels shows no significant differences between the groups. However, there were significant differences in euploid, aneuploidy rates among the BMI groups(≥25 kg/m²vs <18.5 kg/m²; 18.5-25 kg/m²vs <18.5 kg/m²). Both AMH levels and euploidy rates were positively correlated with the number of viable embryos, while the aneuploidy rate was correlated negatively. The>1.68 ng/mL AMH group had significantly higher euploidy and lower aneuploidy rates. AMH levels negatively correlated with aneuploidy rates. Conclusion: AMH levels serve as a valuable predictor of embryo quality, with the >1.68 ng/mL group showing better quality than the ≤1.68 ng/mL group. AMH levels strongly correlate with female age and the number of biopsy embryos but not BMI. Embryo quality demonstrated a significant decline with increasing female age and a marked improvement with a higher number of biopsy embryos and higher AMH levels. BMI did not linear correlation with embryo quality, thus cannot be considered an independent predictor of embryo quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.